LABORATOIRES EUROMEDIS (ALEMG.PA) Stock Fundamental Analysis
EPA:ALEMG • FR0000075343
4.44 EUR
-0.02 (-0.45%)
Last: Feb 27, 2026, 07:00 PM
Taking everything into account, ALEMG scores 2 out of 10 in our fundamental rating. ALEMG was compared to 63 industry peers in the Health Care Equipment & Supplies industry. ALEMG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALEMG does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year ALEMG has reported negative net income.
- The reported net income has been mixed in the past 5 years: ALEMG reported negative net income in multiple years.
- The reported operating cash flow has been mixed in the past 5 years: ALEMG reported negative operating cash flow in multiple years.
1.2 Ratios
- ALEMG's Return On Assets of -13.77% is on the low side compared to the rest of the industry. ALEMG is outperformed by 75.38% of its industry peers.
- ALEMG has a worse Return On Equity (-33.03%) than 73.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.77% | ||
| ROE | -33.03% | ||
| ROIC | N/A |
ROA(3y)0.89%
ROA(5y)6.05%
ROE(3y)1.29%
ROE(5y)13.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 26.77%, ALEMG is doing worse than 86.15% of the companies in the same industry.
- In the last couple of years the Gross Margin of ALEMG has remained more or less at the same level.
- ALEMG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 26.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.6%
GM growth 5Y1.2%
2. Health
2.1 Basic Checks
- ALEMG has about the same amout of shares outstanding than it did 1 year ago.
- ALEMG has less shares outstanding than it did 5 years ago.
- The debt/assets ratio for ALEMG has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 1.87 indicates that ALEMG is not a great score, but indicates only limited risk for bankruptcy at the moment.
- ALEMG has a Altman-Z score of 1.87. This is in the lower half of the industry: ALEMG underperforms 66.15% of its industry peers.
- A Debt/Equity ratio of 0.52 indicates that ALEMG is somewhat dependend on debt financing.
- With a Debt to Equity ratio value of 0.52, ALEMG perfoms like the industry average, outperforming 43.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.87 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 3.07 indicates that ALEMG has no problem at all paying its short term obligations.
- ALEMG has a Current ratio of 3.07. This is amongst the best in the industry. ALEMG outperforms 84.62% of its industry peers.
- ALEMG has a Quick Ratio of 2.25. This indicates that ALEMG is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 2.25, ALEMG belongs to the top of the industry, outperforming 86.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.07 | ||
| Quick Ratio | 2.25 |
3. Growth
3.1 Past
- ALEMG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -144.11%.
- ALEMG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -26.59%.
- Measured over the past years, ALEMG shows a very negative growth in Revenue. The Revenue has been decreasing by -14.02% on average per year.
EPS 1Y (TTM)-144.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%118.64%
Revenue 1Y (TTM)-26.59%
Revenue growth 3Y-31.34%
Revenue growth 5Y-14.02%
Sales Q2Q%11.95%
3.2 Future
- The Earnings Per Share is expected to grow by 7.07% on average over the next years.
- Based on estimates for the next years, ALEMG will show a very negative growth in Revenue. The Revenue will decrease by -18.80% on average per year.
EPS Next Y8.35%
EPS Next 2Y7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year7.54%
Revenue Next 2Y-18.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- ALEMG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- A Price/Forward Earnings ratio of 9.40 indicates a reasonable valuation of ALEMG.
- Based on the Price/Forward Earnings ratio, ALEMG is valued cheaply inside the industry as 93.85% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Forward Earnings ratio of 28.05, ALEMG is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.4 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ALEMG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.07%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- ALEMG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:ALEMG (2/27/2026, 7:00:00 PM)
4.44
-0.02 (-0.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-27 2025-10-27
Earnings (Next)04-23 2026-04-23
Inst Owners1.67%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap12.74M
Revenue(TTM)38.40M
Net Income(TTM)-5.48M
Analysts37.14
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.4 | ||
| P/S | 0.33 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.77 | ||
| P/tB | 0.77 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.93
EYN/A
EPS(NY)0.47
Fwd EY10.64%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS13.38
BVpS5.78
TBVpS5.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.77% | ||
| ROE | -33.03% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 26.77% | ||
| FCFM | N/A |
ROA(3y)0.89%
ROA(5y)6.05%
ROE(3y)1.29%
ROE(5y)13.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.6%
GM growth 5Y1.2%
F-ScoreN/A
Asset Turnover0.97
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.07 | ||
| Quick Ratio | 2.25 | ||
| Altman-Z | 1.87 |
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-144.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%118.64%
EPS Next Y8.35%
EPS Next 2Y7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.59%
Revenue growth 3Y-31.34%
Revenue growth 5Y-14.02%
Sales Q2Q%11.95%
Revenue Next Year7.54%
Revenue Next 2Y-18.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y68.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.57%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
LABORATOIRES EUROMEDIS / ALEMG.PA FAQ
What is the ChartMill fundamental rating of LABORATOIRES EUROMEDIS (ALEMG.PA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to ALEMG.PA.
Can you provide the valuation status for LABORATOIRES EUROMEDIS?
ChartMill assigns a valuation rating of 3 / 10 to LABORATOIRES EUROMEDIS (ALEMG.PA). This can be considered as Overvalued.
What is the profitability of ALEMG stock?
LABORATOIRES EUROMEDIS (ALEMG.PA) has a profitability rating of 1 / 10.
How financially healthy is LABORATOIRES EUROMEDIS?
The financial health rating of LABORATOIRES EUROMEDIS (ALEMG.PA) is 5 / 10.
How sustainable is the dividend of LABORATOIRES EUROMEDIS (ALEMG.PA) stock?
The dividend rating of LABORATOIRES EUROMEDIS (ALEMG.PA) is 0 / 10 and the dividend payout ratio is 0%.